Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00520585

Acronym

ATORVA

Enrollment

Unknown

Registered

2007-08-24

Start date

2007-08-31

Completion date

2007-11-30

Last updated

2007-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Changes of Cardiomyocytes Repolarisation, Heterogeneity of Cardiomyocytes Repolarisation

Keywords

atorvastatin, repolarisation, cardiomyocytes

Brief summary

The aim of this study is to evaluate influence of atorvastin on the repolarisation phase of cardiomyocytes. If there is any, it could be a part of positive non-lipid effect of statins in therapy of ischaemic heart disease. Study hypothesis: atorvastin will decrease heterogeneity of repolarisation of cardiomyocytes in comparison with placebo

Detailed description

The group will consist of 40 healthy volunteers. The study will be mono-centric. The repolarisation phase of cardiomyocytes will be evaluated using long - term 12-lead digital ECG monitoring. There will be 3 single ECG recordings - randomly after 20 mg of atorvastin, 80 mg of atorvastatin and placebo, respectively.

Interventions

DRUGatorvastatin

atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* signed informed consent * age 18 - 45 years

Exclusion criteria

* no chronic active disease * no concomitant pharmacotherapy, excluding hormonal contraception * abnormal ECG, echocardiography, laboratory findings * known hypersensitivity or myopathy due o statin * pregnancy, lactation, breast implants * skin disease

Contacts

Primary ContactOndrej Toman, MD

ondrej.toman@atlas.cz+420532232651

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026